A few, high profile disasters in clinical trials in recent years have thrust the area of human subject research into the regulatory spotlight. The US has been quickest to react to public concern by introducing systems to tighten-up oversight mechanisms. The UK is now examining its clinical policies and here the authors question the best way forrward.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
George, A., Gale, R., Winston, R. et al. Research governance at the crossroads. Nat Med 8, 99–101 (2002). https://doi.org/10.1038/nm0202-99
Issue Date:
DOI: https://doi.org/10.1038/nm0202-99